Graf Susan E

VP, Corp Development & Strateg at NPS PHARMACEUTICALS INC

Sold, on record
$308k
Dollars the filings state
Form 4 sales
1
Latest Feb 10, 2015
Form 144 notices
0
Proposed sales
Companies
1
Filed as an executive or holder

Companies

Sales by reason

0
Routine
0
Plan not stated
0
No plan
1
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per year, every sale on record.

Sales chart range

Timeline

  1. Feb 10, 2015Unusual

    NPS PHARMACEUTICALS INC

    Sold 63.8% of their holdings

    $308k6,711 shares at $45.87

    Filed Feb 11, 2015Form 4

1 of 1

Every transaction

Every transaction on a Form 4 or Form 5 by Graf Susan E
TradedFiledStockRoleWhatAmountPriceValueHeld afterSource
Aug 14, 2026Aug 21, 2026AARDDirectorAwardedStock Option (right to buy)44,96444,964SEC
Jun 4, 2026Jun 5, 2026CGONDirectorAwardedDirector Stock Option (right to buy)9,3549,354SEC
Jun 11, 2025Jun 13, 2025AARDDirectorAwardedStock Option (right to buy)30,50830,508SEC
Jun 5, 2025Jun 6, 2025CGONDirectorAwardedDirector Stock Option (right to buy)24,16524,165SEC
Oct 4, 2024Oct 7, 2024CGONDirectorAwardedStock Option (Right to Buy)15,60015,600SEC
Jun 9, 2023Jun 9, 2023Finch Therapeutics Group, Inc.DirectorBought5,010$0.27$1k5,010SEC
Jun 8, 2023Jun 9, 2023Finch Therapeutics Group, Inc.DirectorAwardedStock Option (right to buy)10,00010,000SEC
Jun 13, 2022Jun 15, 2022Finch Therapeutics Group, Inc.DirectorAwardedStock Option (right to buy)44,84344,843SEC
Apr 23, 2021Apr 27, 2021Finch Therapeutics Group, Inc.DirectorAwardedStock Option (right to buy)23,41923,419SEC
Feb 9, 2018Feb 13, 2018Epizyme, Inc.Chief Business OfficerAwardedStock Option (Right to Buy)106,344106,344SEC
Feb 8, 2017Feb 9, 2017Epizyme, Inc.Chief Business OfficerAwardedStock Option (Right to Buy)109,866109,866SEC
Apr 25, 2016Apr 26, 2016Epizyme, Inc.Chief Business OfficerAwardedStock Option (Right to Buy)178,642178,642SEC
Feb 21, 2015Feb 24, 2015NPS PHARMACEUTICALS INCVP,Corp Development & StrategyTendered4,761$46.00$219k0SEC
Feb 21, 2015Feb 24, 2015NPS PHARMACEUTICALS INCVP,Corp Development & StrategyReturned to the companyStock Options (right to buy)78,5380SEC
Feb 12, 2015Feb 20, 2015NPS PHARMACEUTICALS INCVP,Corp Development & StrategyExercised or settledRestricted Stock Units1,4452,893SEC
Feb 12, 2015Feb 20, 2015NPS PHARMACEUTICALS INCVP,Corp Development & StrategyExercised options1,4455,245SEC
Feb 12, 2015Feb 20, 2015NPS PHARMACEUTICALS INCVP,Corp Development & StrategyWithheld for tax484$45.85$22k4,761SEC
Feb 12, 2015Feb 20, 2015NPS PHARMACEUTICALS INCVP,Corp Development & StrategyAwardedRestricted Stock Units10,90510,905SEC
Feb 10, 2015Feb 11, 2015NPS PHARMACEUTICALS INCVP, Corp Development & StrategSold6,711$45.87$308k3,800SEC
Feb 10, 2015Feb 11, 2015NPS PHARMACEUTICALS INCVP, Corp Development & StrategExercised or settledEmployee Stock Options (right to buy)6,71141,289SEC
Feb 10, 2015Feb 11, 2015NPS PHARMACEUTICALS INCVP, Corp Development & StrategExercised options6,711$14.90$100k10,511SEC
Jun 17, 2014Jun 19, 2014NPS PHARMACEUTICALS INCVP,Corp Development & StrategyExercised or settledRestricted Stock Units5,78811,577SEC
Jun 17, 2014Jun 19, 2014NPS PHARMACEUTICALS INCVP,Corp Development & StrategyExercised options5,7885,788SEC
Jun 17, 2014Jun 19, 2014NPS PHARMACEUTICALS INCVP,Corp Development & StrategyWithheld for tax1,988$33.10$66k3,800SEC
Feb 12, 2014Feb 14, 2014NPS PHARMACEUTICALS INCVP Corp Development & StrategyAwardedEmployee Stock Options (right to buy)16,2124,338SEC
Jun 17, 2013Jun 18, 2013NPS PHARMACEUTICALS INCVP Corp Development & StrategyAwardedEmployee Stock Options (right to buy)65,36517,365SEC

Sales and notices (1)

Form 144 notices and Form 4 sales by Graf Susan E
Source
Feb 10, 2015Feb 11, 2015NPS PHARMACEUTICALS INCVP, Corp Development & StrategForm 4 sale6,711$308k63.8%UnusualSEC